ONCASPAR
Biological
Servier Affaires Medicales
Total Payments
$41.3M
Transactions
3,622
Doctors
1,043
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $8.4M | 312 | 127 |
| 2021 | $10.2M | 216 | 153 |
| 2020 | $11.0M | 190 | 98 |
| 2019 | $6.5M | 914 | 276 |
| 2018 | $2.3M | 883 | 355 |
| 2017 | $2.9M | 1,107 | 418 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $39.9M | 65 | 96.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $783,785 | 263 | 1.9% |
| Consulting Fee | $204,550 | 58 | 0.5% |
| Travel and Lodging | $129,775 | 698 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $93,079 | 60 | 0.2% |
| Food and Beverage | $82,303 | 2,357 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $74,051 | 34 | 0.2% |
| Education | $1,020 | 87 | 0.0% |
Payments by Type
Research
$39.9M
65 transactions
General
$1.4M
3,557 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| DFCI ALL CONSORTIUM PROTOCOL 16-001: RANDOMIZED COMPARISON OF FIXED DOSING VS. PHARMACOKINETICALLY GUIDED DOSE-ADJUSTED ADMINISTRATION OF PEGASPARGASE IN CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED ALL | Servier Affaires Medicales | $17.0M | 0 |
| TREATMENT OF NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS | Servier BioInnovation | $8.1M | 0 |
| DFCI ALL Consortium Protocol 16-001 Randomized comparison of fixed dosing vs. pharmacokinetically guided dose-adjusted administration of Pegaspargase in children and adolescents with newly diagnosed ALL | SERVIER AFFAIRES MEDICALES | $2.4M | 0 |
| RANDOMIZED COMPARISON OF FIXED DOSING VS. PHARMACOKINETICALLY GUIDED DOSE-ADJUSTED ADMINISTRATION OF PEGASPARGASE IN CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED ALL | Shire North American Group Inc | $1.9M | 0 |
| DFCI ALL Consortium Protocol 16-001 Randomized comparison of fixed dosing vs. pharmacokinetically guided dose-adjusted administration of Pegaspargase in children and adolescents with newly diagnosed ALL | Servier Affaires Medicales | $1.8M | 0 |
| DFCI ALL Consortium Protocol 16-001 Randomized Comparison of Fixed Dosing vs. Pharmacokinetically Guided Dose-Adjusted Administration of Calaspargase Pegol in Children and Adolescents with newly diagnosed ALL | Servier Affaires Medicales | $1.7M | 0 |
| Treatment of Newly Diagnosed Acute LymphoblasticLeukemiain Children and Adolescents | Servier Pharmaceuticals LLC | $1.7M | 0 |
| TREATMENT OF NEWLY DIAGNOSED ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND ADOLESCENTS | Servier Affaires Medicales | $1.3M | 0 |
| DFCI ALL CONSORTIUM PROTOCOL 16-001: RANDOMIZED COMPARISON OF FIXED DOSING VS. PHARMACOKINETICALLY GUIDED DOSE-ADJUSTED ADMINISTRATION OF CALASPARGASE PEGOL IN CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED ALL | Servier Affaires Medicales | $970,147 | 0 |
| A phase III randomized trial of Blinatumomab for newly diagnosed bcr-abl-negative lineage acute lymphoblastic leukemia in adults | Servier Affaires Medicales | $930,787 | 0 |
| TOTXVII Total therapy study XVII for newly diagnosed patients with Acute Lymphoblastic Leukemia and Lymphoma | Servier Affaires Medicales | $528,734 | 0 |
| TOTAL XVII PROTOCOL ASPARAGINASE STUDIES | Shire North American Group Inc | $264,367 | 0 |
| Preventing ASNase-associated pancreatitis using the novel dimension of metabolomics and proteomics | Servier BioInnovation | $244,950 | 0 |
| Preventing ASNase-associated pancreatitis using the novel dimension of metabolomics | Servier Affaires Medicales | $139,172 | 0 |
| A NOVEL PEDIATRIC-INSPIRED REGIMEN WITH REDUCED MYELOSUPPRESSIVE DRUGS FOR ADULTS AGED 18-60 WITH NEWLY DIAGNOSED PH NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA | Shire North American Group Inc | $129,550 | 0 |
| A novel Pediatric-Inspired Regimen with Reduced Myelosuppressive Drugs for Adults aged 18-60 with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia | Servier Affaires Medicales | $125,210 | 0 |
| A Study on Drug Monitoring of Asparaginase Activity in Pediatric Patients with Acute Lymphoblastic Leukemia | Servier Pharmaceuticals LLC | $105,397 | 0 |
| A PHASE II STUDY OF PUNCTUAL, CYCLIC, AND INTENSIVE CHEMOTHERAPY WITH LIPOSOMAL CYTARABINE DEPOCYT CNS PROPHYLAXIS FOR ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AND LYMPHOBLASTIC LYMPHOMA | Shire North American Group Inc | $100,771 | 0 |
| A041501-PP1 Evaluation of Asparaginase pharmacokinetics and its effect on toxicities and clinical outcomes in Adolescents and Young Adults with newly diagnosed precursor B-Cell ALL | Servier Affaires Medicales | $91,773 | 0 |
| Evaluation of Health Burden in Adolescent and Young Adult Survivors of Acute Lymphoblastic Leukemia Therapy | Servier Affaires Medicales | $87,988 | 0 |
Top Doctors Receiving Payments for ONCASPAR — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD, MS | Pediatrics | Los Angeles, CA | $5,075 | 15 |
| , M.D | Internal Medicine | Chicago, IL | $4,689 | 12 |
| , MD, PHD | Internal Medicine | Baltimore, MD | $4,579 | 10 |
| , DO | Obstetrics & Gynecology | Charlotte, NC | $4,019 | 5 |
| , M.D | Internal Medicine | La Crescenta, CA | $4,001 | 4 |
| , MD | Pediatric Hematology-Oncology | Hawthorne, NY | $3,949 | 9 |
| , M.D., PH.D | Medical Oncology | Orange, CA | $3,861 | 6 |
| John Quigley | Hematology & Oncology | Chicago, IL | $3,713 | 6 |
| , MD | Hematology & Oncology | Salt Lake Cty, UT | $3,110 | 5 |
| , MD | Hematology | Madison, WI | $3,108 | 5 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $2,617 | 4 |
| , M.D | Pediatric Hematology-Oncology | San Antonio, TX | $2,589 | 6 |
| , M.D | Hematology & Oncology | Springfield, NJ | $2,375 | 10 |
| , MD | Pediatrics | Boston, MA | $2,340 | 4 |
| , MD | Internal Medicine | New York, NY | $2,060 | 2 |
| , MD | Pediatric Hematology-Oncology | Miami, FL | $2,040 | 2 |
| , M.D | Internal Medicine | Spartanburg, SC | $1,735 | 2 |
| , MD | Hematology & Oncology | New York, NY | $1,700 | 1 |
| , MD | Pediatric Hematology-Oncology | Tampa, FL | $1,670 | 2 |
| , M.D | Pediatric Hematology-Oncology | Bend, OR | $1,500 | 1 |
| , MD PHD FRCP | Internal Medicine | Detroit, MI | $1,413 | 3 |
| , MD, PHD | Internal Medicine | Boston, MA | $1,220 | 2 |
| , MD | Pediatric Hematology-Oncology | Salt Lake City, UT | $1,000 | 1 |
| , M.D | Hematology & Oncology | Murray, UT | $900.00 | 1 |
| , MD | Pediatric Hematology-Oncology | Boston, MA | $873.53 | 3 |
Ad
Manufacturing Companies
- Servier Affaires Medicales $24.9M
- Servier BioInnovation $8.3M
- Shire North American Group Inc $3.2M
- SERVIER AFFAIRES MEDICALES $2.4M
- Servier Pharmaceuticals LLC $2.4M
- SERVIER PHARMACEUTICALS LLC $99,220
- LES LABORATOIRES SERVIER $5,500
Product Information
- Type Biological
- Total Payments $41.3M
- Total Doctors 1,043
- Transactions 3,622
About ONCASPAR
ONCASPAR is a biological associated with $41.3M in payments to 1,043 healthcare providers, recorded across 3,622 transactions in the CMS Open Payments database. The primary manufacturer is Servier Affaires Medicales.
Payment data is available from 2017 to 2022. In 2022, $8.4M was paid across 312 transactions to 127 doctors.
The most common payment nature for ONCASPAR is "Unspecified" ($39.9M, 96.7% of total).
ONCASPAR is associated with 20 research studies, including "DFCI ALL CONSORTIUM PROTOCOL 16-001: RANDOMIZED COMPARISON OF FIXED DOSING VS. PHARMACOKINETICALLY GUIDED DOSE-ADJUSTED ADMINISTRATION OF PEGASPARGASE IN CHILDREN AND ADOLESCENTS WITH NEWLY DIAGNOSED ALL" ($17.0M).